Literature DB >> 8864187

Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis.

G M Kirby1, G Batist, L Alpert, E Lamoureux, R G Cameron, M A Alaoui-Jamali.   

Abstract

Studies were carried out to test the hypothesis that inflammatory liver disease increases the expression of specific cytochrome P-450 isoenzymes involved in aflatoxin B1 (AFB) activation. The immunohistochemical expression and localization of various human cytochrome P-450 isoforms, including CYP2A6, CYP1A2, CYP3A4, and CYP2B1, were examined in normal human liver and liver with hepatitis and cirrhosis. The constitutive expression of CYP3A4 in normal liver showed a characteristic pattern of distribution in centrilobular hepatocytes, whereas CYP1A2, CYP2A6, and CYP2B1 were expressed uniformly throughout the liver acinus. In sections of liver infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), the expression of CYP2A6 was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation. CYP3A4 and CYP2B1 were induced to a lesser degree, and expression of CYP1A2 was unaffected. In HBV-infected liver, double immunostaining revealed that overexpression of CYP2A6 occurred in hepatocytes expressing the HBV core antigen. In HCV-infected liver, CYP2A6, CYP3A4, and CYP2B1 were overexpressed in hepatocytes with hemosiderin pigmentation. These results suggest that alterations in phenotypic expression of specific P-450 isoenzymes in hepatocytes associated with hepatic inflammation and cirrhosis might increase susceptibility to AFB genotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864187     DOI: 10.1177/019262339602400408

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  18 in total

1.  Effect of hepatitis B and C clearance on atazanavir exposure.

Authors:  Cristina Gervasoni; Dario Cattaneo; Valeria Micheli; Valentina Di Cristo; Laura Milazzo
Journal:  Eur J Clin Pharmacol       Date:  2015-08-23       Impact factor: 2.953

2.  Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

3.  Differential response related to genotoxicity in multiple organs of cirrhotic rats.

Authors:  Marcia R Nagaoka; Luciana Le Sueur-Maluf; Odair Aguiar; Glaucia M Castro; Regina C Spadari-Bratfisch; Daniel A Ribeiro
Journal:  Hepatol Int       Date:  2011-01-06       Impact factor: 6.047

Review 4.  Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Authors:  Kelly L Hayward; Elizabeth E Powell; Katharine M Irvine; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

5.  Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes.

Authors:  J C Davila; D L Morris
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-03       Impact factor: 2.416

6.  Pyrazole-inducible proteins in DBA/2 mouse liver bind with high affinity to the 3'-untranslated regions of the mRNAs of coumarin hydroxylase (CYP2A5) and c-jun.

Authors:  M Thulke-Gross; M Hergenhahn; A Tilloy-Ellul; M Lang; H Bartsch
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

7.  Phenotypic CYP2A6 variation and the risk of pancreatic cancer.

Authors:  Susan Kadlubar; Jeffrey P Anderson; Carol Sweeney; Myron D Gross; Nicholas P Lang; Fred F Kadlubar; Kristin E Anderson
Journal:  JOP       Date:  2009-05-18

8.  Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures.

Authors:  Jonathan P Jackson; Linhou Li; Erica D Chamberlain; Hongbing Wang; Stephen S Ferguson
Journal:  Drug Metab Dispos       Date:  2016-06-23       Impact factor: 3.922

9.  Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.

Authors:  William C Wright; Jude Chenge; Jingheng Wang; Hazel M Girvan; Lei Yang; Sergio C Chai; Andrew D Huber; Jing Wu; Peter O Oladimeji; Andrew W Munro; Taosheng Chen
Journal:  J Med Chem       Date:  2020-01-22       Impact factor: 7.446

10.  Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; James Ranger-Moore; Jonathan P Jackson; Stephen S Ferguson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2009-08-03       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.